{"id":411585,"date":"2021-01-11T06:03:12","date_gmt":"2021-01-11T11:03:12","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=411585"},"modified":"2021-01-11T06:03:12","modified_gmt":"2021-01-11T11:03:12","slug":"neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","title":{"rendered":"NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference"},"content":{"rendered":"
\n

PITTSBURGH, Jan. 11, 2021 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (\u201cNeuBase\u201d or the \u201cCompany\u201d), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview during the H.C. Wainwright Virtual BioConnect Conference, which is being held from January 11 – 14, 2021. A webcast of the on-demand presentation will be available beginning today at 6:00 a.m. Eastern Time and archived on the NeuBase website, www.neubasetherapeutics.com<\/a>.\u00a0\u00a0<\/p>\n

\n About NeuBase Therapeutics
<\/strong>NeuBase is accelerating the genetic revolution using a new class of synthetic medicines. NeuBase\u2019s designer PATrOL\u2122 therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit\u00a0www.neubasetherapeutics.com<\/a>.<\/p>\n

\n NeuBase Investor Contact:<\/strong>
\n
Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com<\/a>
OP: (617) 430-7576<\/p>\n

\n NeuBase Media Contact:<\/strong>
\n
Cait Williamson, Ph.D.
LifeSci Public Relations
cait@lifescipublicrelations.com<\/a>
OP: (646) 751-4366<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PITTSBURGH, Jan. 11, 2021 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (\u201cNeuBase\u201d or the \u201cCompany\u201d), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview during the H.C. Wainwright Virtual BioConnect Conference, which is being held from January 11 – 14, 2021. A webcast of the on-demand presentation will be available beginning today at 6:00 a.m. Eastern Time and archived on the NeuBase website, www.neubasetherapeutics.com.\u00a0\u00a0 About NeuBase TherapeuticsNeuBase is accelerating the genetic revolution using a new class of synthetic medicines. NeuBase\u2019s designer PATrOL\u2122 therapies are centered around its proprietary drug scaffold to address genetic diseases at the source … <\/p>\n

Continue reading “NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-411585","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PITTSBURGH, Jan. 11, 2021 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (\u201cNeuBase\u201d or the \u201cCompany\u201d), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview during the H.C. Wainwright Virtual BioConnect Conference, which is being held from January 11 – 14, 2021. A webcast of the on-demand presentation will be available beginning today at 6:00 a.m. Eastern Time and archived on the NeuBase website, www.neubasetherapeutics.com.\u00a0\u00a0 About NeuBase TherapeuticsNeuBase is accelerating the genetic revolution using a new class of synthetic medicines. NeuBase\u2019s designer PATrOL\u2122 therapies are centered around its proprietary drug scaffold to address genetic diseases at the source … Continue reading "NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-11T11:03:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzQxMCMzOTEyMzIyIzUwMDA2NDg3Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference\",\"datePublished\":\"2021-01-11T11:03:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\"},\"wordCount\":219,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzQxMCMzOTEyMzIyIzUwMDA2NDg3Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\",\"name\":\"NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzQxMCMzOTEyMzIyIzUwMDA2NDg3Ng==\",\"datePublished\":\"2021-01-11T11:03:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzQxMCMzOTEyMzIyIzUwMDA2NDg3Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzQxMCMzOTEyMzIyIzUwMDA2NDg3Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","og_locale":"en_US","og_type":"article","og_title":"NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk","og_description":"PITTSBURGH, Jan. 11, 2021 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (\u201cNeuBase\u201d or the \u201cCompany\u201d), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview during the H.C. Wainwright Virtual BioConnect Conference, which is being held from January 11 – 14, 2021. A webcast of the on-demand presentation will be available beginning today at 6:00 a.m. Eastern Time and archived on the NeuBase website, www.neubasetherapeutics.com.\u00a0\u00a0 About NeuBase TherapeuticsNeuBase is accelerating the genetic revolution using a new class of synthetic medicines. NeuBase\u2019s designer PATrOL\u2122 therapies are centered around its proprietary drug scaffold to address genetic diseases at the source … Continue reading \"NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-11T11:03:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzQxMCMzOTEyMzIyIzUwMDA2NDg3Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference","datePublished":"2021-01-11T11:03:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/"},"wordCount":219,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzQxMCMzOTEyMzIyIzUwMDA2NDg3Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","name":"NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzQxMCMzOTEyMzIyIzUwMDA2NDg3Ng==","datePublished":"2021-01-11T11:03:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzQxMCMzOTEyMzIyIzUwMDA2NDg3Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzQxMCMzOTEyMzIyIzUwMDA2NDg3Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=411585"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411585\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=411585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=411585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=411585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}